clinical trial · NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC·phase2·active not recruiting·n = 333
Leukemia, Lymphocytic, Chronic, B-CellSmall Lymphocytic LymphomaIbrutinibVenetoclax
brief summary
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
started
May 30, 2024
primary completion
Dec 15, 2027
completion
Mar 19, 2029
last updated
Jul 31, 2026
official title
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol